Abstract
Aims: To investigate prescribing patterns to prevent steroid induced osteoporosis. To compare prophylactic prescribing with National Osteoporosis Society (NOS) guidelines.
Method: All patients (n=92) taking oral corticosteroids admitted to general medical wards at a district general hospital were prospectively investigated over a nine month period.
Results: Variations from recommended management were revealed. Altogether 64.7% of all inpatients who qualified for prophylaxis for steroid induced osteoporosis were not provided with any suitable agent. It was also found that 21.6% of those who qualified for treatment received a bisphosphonate, the only treatment currently licensed for preventing steroid induced osteoporosis. Of those prescribed prophylactic treatment, a bisphosphonate was selected for 39.3%, hormone replacement therapy was given to 25.0%, and 35.7% received treatment that is not recommended in NOS guidelines.
Conclusion: This study revealed substantial variations from NOS guidelines. It is suggested that osteoporosis prophylaxis during steroid treatment is promoted by local hospital guidelines, hospital and community pharmacists, audit, and general practitioners.
Full Text
The Full Text of this article is available as a PDF (71.8 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Adachi J. D., Bensen W. G., Brown J., Hanley D., Hodsman A., Josse R., Kendler D. L., Lentle B., Olszynski W., Ste-Marie L. G. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med. 1997 Aug 7;337(6):382–387. doi: 10.1056/NEJM199708073370603. [DOI] [PubMed] [Google Scholar]
- Eastell R., Reid D. M., Compston J., Cooper C., Fogelman I., Francis R. M., Hosking D. J., Purdie D. W., Ralston S. H., Reeve J. A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update. J Intern Med. 1998 Oct;244(4):271–292. doi: 10.1046/j.1365-2796.1998.00408.x. [DOI] [PubMed] [Google Scholar]
- Peat I. D., Healy S., Reid D. M., Ralston S. H. Steroid induced osteoporosis: an opportunity for prevention? Ann Rheum Dis. 1995 Jan;54(1):66–68. doi: 10.1136/ard.54.1.66. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Saag K. G., Emkey R., Schnitzer T. J., Brown J. P., Hawkins F., Goemaere S., Thamsborg G., Liberman U. A., Delmas P. D., Malice M. P. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med. 1998 Jul 30;339(5):292–299. doi: 10.1056/NEJM199807303390502. [DOI] [PubMed] [Google Scholar]
- Sambrook P., Birmingham J., Kempler S., Kelly P., Eberl S., Pocock N., Yeates M., Eisman J. Corticosteroid effects on proximal femur bone loss. J Bone Miner Res. 1990 Dec;5(12):1211–1216. doi: 10.1002/jbmr.5650051204. [DOI] [PubMed] [Google Scholar]
- Stevenson J. C. Management of corticosteroid-induced osteoporosis. Lancet. 1998 Oct 24;352(9137):1327–1328. doi: 10.1016/s0140-6736(05)60740-4. [DOI] [PubMed] [Google Scholar]
- Walsh L. J., Wong C. A., Pringle M., Tattersfield A. E. Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study. BMJ. 1996 Aug 10;313(7053):344–346. doi: 10.1136/bmj.313.7053.344. [DOI] [PMC free article] [PubMed] [Google Scholar]